A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies

Drug Discov Today. 2024 Jan 23;29(3):103893. doi: 10.1016/j.drudis.2024.103893. Online ahead of print.ABSTRACTCD40, a novel immunomodulatory cancer therapy target, is expressed by B cells, macrophages, and dendritic cells (DCs) and mediates cytotoxic T cell priming through the CD40 ligand. Some tumors show promising responses to monotherapy or combination therapy with agonistic anti-CD40 antibodies. The development of improved anti-CD40 antibodies makes CD40 activation an innovative strategy in cancer immunotherapy. In this review, we trace the history of CD40 research and summarize preclinical and clinical findings. We emphasize the ongoing development of improved anti-CD40 antibodies and explore strategies for effective combination therapies. Guided by predictive biomarkers, future research should identify patient populations benefiting the most from CD40 activation.PMID:38272173 | DOI:10.1016/j.drudis.2024.103893
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research